Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Euro Surveill ; 27(22)2022 06.
Article in English | MEDLINE | ID: covidwho-1879391

ABSTRACT

German national surveillance data analysis shows that hospitalisation odds associated with Omicron lineage BA.1 or BA.2 infections are up to 80% lower than with Delta infection, primarily in ≥ 35-year-olds. Hospitalised vaccinated Omicron cases' proportions (2.3% for both lineages) seemed lower than those of the unvaccinated (4.4% for both lineages). Independent of vaccination status, the hospitalisation frequency among cases with Delta seemed nearly threefold higher (8.3%) than with Omicron (3.0% for both lineages), suggesting that Omicron inherently causes less severe disease.


Subject(s)
COVID-19 , SARS-CoV-2 , Germany/epidemiology , Humans , SARS-CoV-2/genetics , Severity of Illness Index
3.
SSRN; 2022.
Preprint in English | SSRN | ID: ppcovidwho-332511

ABSTRACT

Background: mRNA-based COVID-19 booster vaccinations have been administered in Germany since mid-September 2021. We utilized Germany’s national COVID-19 surveillance data to assess effectiveness of three vaccination doses among adolescents and adults during Delta- and Omicron-predominance. Methods: We applied a quasi-Poisson regression model to estimate incidence rate ratios and 95% confidence intervals for symptomatic SARS-CoV-2 infection and COVID-19 associated hospitalization and severe illness by age group (12-17, 18-59, and ≥60 years). We further investigated waning of vaccine effectiveness (VE) over time during Omicron-predominance. Findings: VE against symptomatic infection was considerably lower during Omicron- versus Delta-predominance (70% vs. 95% among ≥18 year-olds). During Omicron-predominance, estimated 3-dose VE at <4 weeks post-vaccination was highest in 12-17 year-olds (89·7%), followed by ≥60 year-olds (87·8%) and 18-59 year-olds (77·4%), and declined to 84·4% at 4 to <8 weeks post-vaccination and 51·1% and 76·4% at 8 to <12 weeks post-vaccination, respectively. VE against hospitalization was high in all age groups and remained >90% among ≥60 year-olds and >75% among 18-59 year-olds at 8 to <12 weeks post-vaccination, while VE against severe illness among ≥60 year-olds was >95% at 8 to <12 weeks. Interpretation: First estimates for effectiveness of mRNA booster vaccinations against Omicron-infections in adolescents are encouragingly high. Waning of protection against mild illness over the first 15 weeks post-vaccination was marked among 18-59 year-olds;however, boosting offered excellent protection against hospitalization and severe illness. Utilizing routine surveillance data to monitor COVID-19 VE in real time can be a valid and resource-saving approach upon surge of novel SARS-CoV-2 variants.

4.
Epidemiol Infect ; : 1-9, 2022 Jan 07.
Article in English | MEDLINE | ID: covidwho-1630682
5.
Euro Surveill ; 26(21)2021 05.
Article in English | MEDLINE | ID: covidwho-1247780

ABSTRACT

We investigated three SARS-CoV-2 variant B.1.1.7 childcare centre and related household outbreaks. Despite group cohorting, cases occurred in almost all groups, i.e. also among persons without close contact. Children's secondary attack rates (SAR) were similar to adults (childcare centres: 23% vs 30%; p = 0.15; households: 32% vs 39%; p = 0.27); child- and adult-induced household outbreaks also led to similar SAR. With the advent of B.1.1.7, susceptibility and infectiousness of children and adults seem to converge. Public health measures should be revisited accordingly.


Subject(s)
COVID-19 , SARS-CoV-2 , Adult , Child , Disease Outbreaks , Germany/epidemiology , Humans
6.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz ; 64(4): 395-402, 2021 Apr.
Article in German | MEDLINE | ID: covidwho-1196564

ABSTRACT

As part of the national influenza pandemic preparedness, surveillance systems have been established in Germany in addition to the mandatory notifications according to the Protection Against Infection Act. The aim of these systems is the description, analysis, and evaluation of the epidemiology of acute respiratory infections (ARIs), the identification of the circulating viruses, and the trend. Since the beginning of the COVID-19 pandemic, the systems have been expanded to enable monitoring of infections with SARS-CoV­2.Three systems are presented: GrippeWeb, the primary care sentinel Arbeitsgemeinschaft Influenza with its electronic reporting module SEEDARE, and the ICD-10-based hospital sentinel ICOSARI. With these systems, ARIs can be monitored at the population, outpatient, and inpatient levels. In combination with the monitoring of mortality, these systems provide important information on the frequency of different stages of disease severity in the population. In order to expand the systems to SARS-CoV­2, only a few adjustments were needed.As the case definitions for ARIs were preserved, historical baselines of the systems can still be used for comparison. All systems are structured in such a way that stable and established reference values are available for calculating weekly proportions and rates.This is an important addition to the mandatory reporting system of infectious diseases in Germany, which depends on the particular testing strategy, the number of tests performed, and on specific case definitions, which are adapted as required.The surveillance systems have proven to be feasible and efficient in the COVID-19 pandemic, even when compared internationally.


Subject(s)
COVID-19 , Respiratory Tract Infections , Germany/epidemiology , Humans , Pandemics/prevention & control , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/epidemiology , SARS-CoV-2
7.
Euro Surveill ; 26(2)2021 01.
Article in English | MEDLINE | ID: covidwho-1067623

ABSTRACT

The European monitoring of excess mortality for public health action (EuroMOMO) network monitors weekly excess all-cause mortality in 27 European countries or subnational areas. During the first wave of the coronavirus disease (COVID-19) pandemic in Europe in spring 2020, several countries experienced extraordinarily high levels of excess mortality. Europe is currently seeing another upsurge in COVID-19 cases, and EuroMOMO is again witnessing a substantial excess all-cause mortality attributable to COVID-19.


Subject(s)
COVID-19/mortality , Mortality/trends , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/epidemiology , Cause of Death , Child , Child, Preschool , Computer Systems , Epidemiological Monitoring , Europe/epidemiology , Humans , Infant , Infant, Newborn , Middle Aged , SARS-CoV-2 , Young Adult
8.
Euro Surveill ; 25(26)2020 07.
Article in English | MEDLINE | ID: covidwho-639161

ABSTRACT

A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds.


Subject(s)
Cause of Death/trends , Coronavirus Infections/mortality , Coronavirus/isolation & purification , Influenza, Human/mortality , Pneumonia, Viral/mortality , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Betacoronavirus , COVID-19 , Child , Child, Preschool , Coronavirus Infections/diagnosis , Disease Outbreaks , Europe/epidemiology , Female , Humans , Infant , Infant, Newborn , Influenza, Human/diagnosis , Male , Middle Aged , Mortality/trends , Pandemics , Pneumonia, Viral/diagnosis , Population Surveillance , Preliminary Data , SARS-CoV-2 , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL